In this proof-of-principle study, we demonstrate that the RUNX1-RUNX1T1 can be targeted and disrupted utilizing a dual intron-targeting CRISPR-Cas9-mediated strategy elucidating this novel methodology’s potential in future treatment of AML t(8;21) patients. The gene discussed is RUNX1; the disease is acute myeloid leukemia.